In my recent talks, I’ve often highlighted that the secretions of MSCs are what is behind their therapeutic effect – this is supported by the findings of several publications investigating their paracrine properties. This 2019 paper extensively reviews the recent research about the role of secreted extracellular vesicles of UC-MSC. The authors go over 35 studies that used extracellular vesicles from UC-MSC to treat diverse conditions in animal models and in vitro (in the lab), with very positive outcomes.
Human umbilical cord mesenchymal stem cell-derived extracellular vesicles: A novel therapeutic paradigm.
Mesenchymal stem cells (MSCs) have been revealed to hold great potential for the development of new treatment approaches for various diseases. However, the clinical use of these cells is limited due to their tumorigenic effects. The therapeutic benefits of MSCs are largely dependent on paracrine factors including extracellular vesicles (EVs). EVs are nano-sized bilayer membrane structures containing lipids, microRNAs and proteins which play key roles in cell-to-cell communications. Because of their lower immunogenicity, tumorigenicity, and easier management, EVs have emerged as a new promising alternative to whole-cell therapy. Therefore, this paper reviews current preclinical studies on the use of EVs derived from human umbilical cord MSCs (hucMSCs) as a therapeutic approach in treatment of several diseases including neurological, cardiovascular, liver, kidney, and bone diseases as well as the cutaneous wound, inflammatory bowel disease, cancers, infertility, and other disorders.
PMID: 31254289 DOI: 10.1002/jcp.29004